DRG Epidemiology's coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations across the Americas (Argentina, Canada, Chile, Colombia, and Peru). We report both the incidence and prevalence of soft tissue sarcoma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at the first line of therapy is also forecast across the major mature pharmaceutical markets.
DRG Epidemiology's soft tissue sarcoma forecast will answer the question:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of soft tissue sarcoma over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following soft tissue sarcoma subpopulations:
Diagnosed incident cases—all sites.
Diagnosed incident cases—by specific sites.
Diagnosed prevalent STS cases—by extent of disease (metastatic or non-metastatic).
Incidence of Soft Tissue Sarcoma of all sites per 100,000 per Year Among People of All Ages in 2020 and 2030
Relative Sizes of the Contributing Factors to the Trend in Incident Cases of Soft Tissue Sarcoma of all sites over the Next 10 Years
Methods
Newly Diagnosed Incidence
Stage Distribution
Recurrent Incidence
Diagnosed Prevalence
Drug-Treatable Populations
Epidemiology Data
Reference Materials
Literature Review
Studies Included in the Analysis of STS
Studies Excluded from the Analysis of STS
Risk/Protective Factors
Risk/Protective Factors for STS
Bibliography
Narendra Parihar
Narendra Parihar, M.P.H., is a principal epidemiologist at Clarivate. His areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. A former dentist, he earned his M.P.H. from the Tata Institute of Social Sciences in Mumbai.
